Navigation Links
Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
Date:3/17/2010

INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14.  

Lilly is working with the U.S. Food and Drug Administration's Office of Criminal Investigations (FDA), and other law enforcement officials, to recover cases of select lots of pharmaceutical products that were stolen from one of Lilly's United States distribution centers located in Enfield, Connecticut, on Sunday, March 14, 2010.  A list of products stolen from the facility can be found at the bottom of this press release.

"Since early Sunday morning, Lilly has taken quick and appropriate actions to ensure the safety of our medicines," said Dr. Fionnuala M. Walsh, Lilly's senior vice president of global quality.  "The U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels. However, we will continue to work closely with local and federal law enforcement authorities, the FDA, and our distribution partners to maintain the integrity of our drug supply chain."

Product from the affected lots which had been delivered from Lilly to retailers, wholesalers or institutions prior to March 14 was approved for its intended use and is not affected by this event.  Product containing these lot numbers has been distributed by Lilly within the United States, Puerto Rico and its territories.

These medicines require a prescription for purchase.  Consumers should purchase Lilly products only from well-established and reputable retailers.  Lilly recommends that consumers always inspect the product and label for signs of tampering before opening.  

Lilly is advising practitioners, retailers and consumers to check all pharmaceutical products for signs of tampering or damage prior to purchase and/or use.  Pharmacists and other health care professionals should not use the product if it has been removed from the sealed bottle or container, if the induction seal has been compromised, or in the case of glass vials, if the flip cap appears to have been disturbed in any way.  

To assist the FDA and the law enforcement agencies in their investigation, Lilly stopped distributing product with the affected lot numbers on Monday, March 15, 2010.

Lilly is asking for the public's help in reporting any information regarding the stolen products to FDA's Office of Criminal Investigations (OCI) by calling (800) 551-3989 or by visiting the OCI website www.fda.gov/OCI.

For medical or other related inquiries about this matter, contact Lilly at 1-800-LILLYRX (1-800-545-5979).

Impacted Products

    
    
                              National Drug Code
    Product Description       (NDC)               Lot Number   Expiry Date
    -------------------       ------------------  ----------   -----------
    ALIMTA FINJ 500MG X1
     lyophilizedVIAL AM       00002-7623-01       A671076C      8/31/2011
    --------------------      -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A643056A      5/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A662278C      7/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A662281A      7/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 60MG X30BOTL
     AM                       00002-3270-30       A672999A      9/30/2011
    ------------------------- -------------       --------      ---------
    CYMBALTA CAP 60MG
     X1000BOTL AM             00002-3270-04       A685790A     10/31/2011
    -----------------         -------------       --------     ----------
    EFFIENT TAB 10MG X30BOTL
     AM                       00002-4759-30       A650259A     12/31/2010
    ------------------------  -------------       --------     ----------
    GEMZAR 200MG VIALS        00002-7501-01       A670185A      8/31/2011
    ------------------        -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A668160D      8/31/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670177A      9/30/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670180A      8/31/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670182A      9/30/2011
    -------------------       -------------       --------      ---------
    PROZAC PULV 20MG X 30
     BOTL DP                  00777-3105-30       A599046D      1/31/2012
    ---------------------     -------------       --------      ---------
    PROZAC PULV 20MG X 30
     BOTL DP                  00777-3105-30       A689619D     10/31/2012
    ---------------------     -------------       --------     ----------
    PROZAC PULV 40MG X 30
     BOTL DP                  00777-3107-30       A602567A      1/31/2012
    ---------------------     -------------       --------      ---------
    STRATTERA CAP 10MG X 30
     BOTL AM                  00002-3227-30       A621189A      3/31/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 25MG X 30
     BOTL AM                  00002-3228-30       A678353A      2/29/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 60MG X 30
     BOTL AM                  00002-3239-30       A621202A      3/31/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 100MG
     X30BOTL AM               00002-3251-30       A621205C      3/31/2012
    -------------------       -------------       --------      ---------
    SYMBYAX CAP 6/25MG X 30
     BOTL AM                  00002-3231-30       A562684A     10/31/2011
    -----------------------   -------------       --------     ----------
    ZYPREXA TAB 2.5MG X30BOTL
     AM                       00002-4112-30       A644710A      5/31/2011
    ------------------------- -------------       --------      ---------
    ZYPREXA TAB 5MG X30BOTL
     AM                       00002-4115-30       A668322A      8/31/2011
    -----------------------   -------------       --------      ---------
    ZYPREXA TAB 7.5MG X30BOTL
     AM                       00002-4116-30       A646193A      5/31/2011
    ------------------------- -------------       --------      ---------
    ZYPREXA TAB 10MG X30BOTL
     AM                       00002-4117-30       A641350C      5/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 10MG X30BOTL
     AM                       00002-4117-30       A668323A      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 15MG X 1000
     BOTL AM                  00002-4415-04       A647860A      5/31/2012
    -----------------------   -------------       --------      ---------
    ZYPREXA TAB 15MG X30BOTL
     AM                       00002-4415-30       A690238A     10/31/2012
    ------------------------  -------------       --------     ----------
    ZYPREXA TAB 20MG X30BOTL
     AM                       00002-4420-30       A677956A      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 20MG X30BOTL
     AM                       00002-4420-30       A677958C      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB ID100 10MG
     XID100BLCD AM            00002-4117-33       A632252D      4/30/2012
    ----------------------    -------------       --------      ---------
    ZYPREXA ZYDIS TAB 5MG X
     30 SACH AM               00002-4453-85       976041A        7/1/2012
    -----------------------   -------------       -------        --------
    ZYPREXA ZYDIS TAB 10MG X
     30 SACH AM               00002-4454-85       971159A        7/1/2012
    ------------------------  -------------       -------        --------
    ZYPREXA ZYDIS TAB 20MG X
     30 SACH AM               00002-4456-85       963999A        5/1/2012
    ------------------------  -------------       -------        --------
    
    

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Alimta® (pemetrexed disodium)

Cymbalta® (duloxetine hydrochloride)

Effient™ (prasugrel)

Gemzar® (gemcitabine hydrochloride)

Prozac® (fluoxetine hydrochloride)

Strattera® (atomoxetine hydrochloride)

Symbyax (olanzapine / fluoxetine hydrochloride)

Zyprexa® (olanzapine)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Back to top
'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
2. Pew Statement on Congressional Hearing Regarding FDA Drug Safety Reforms
3. SCAI Statement on the CREST Study Findings: Carotid Stenting is as Safe and Effective as Carotid Surgery in Patients at Risk for Stroke
4. GSK Statement on FDAs Proposed Label Revisions for Some Asthma Medicines
5. SCAI Statement on the Hospitalization of Former President Bill Clinton
6. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
7. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
9. Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse
10. Sinovac Files Shelf Registration Statement
11. Derma Sciences Files S-1 Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016   ... the importance of extending care beyond the implant at ... Sessions, May 4-7 in San Francisco ... with continually delivering the highest quality of patient care ... patients are cared for each and every tomorrow," said ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
(Date:5/3/2016)... TUSTIN, Calif. , May 3, 2016 /PRNewswire/ ... science teaching tool that shows how a cleanroom ... for classroom discussions about science and technology. ... Manager said, "As a technology company, SSF enthusiastically ... program to help educators foster the next generation ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 05, 2016 , ... Sun Health registered nurse Brittany Eads ... Care Transitions program at the 9th Annual Orthopedic and Spine Summit ... the Post-Acute Environment Through Effective Transitions of Care.” , Major changes are taking ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff ... activity to alleviate the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous ... in people with arthritis. , “Physical therapy exercises are commonly prescribed to ...
(Date:5/5/2016)... Dallas, Texas (PRWEB) , ... May 05, 2016 ... ... and relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the ... Dallas, Texas. , Scott Pettigrew, Vice President and Chief Security Officer of ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 ... and up 27 percent since 2012. , The results of the 2015 ASDS Survey ... increase in skin cancer treatments and the growing popularity of soft-tissue fillers and body ...
Breaking Medicine News(10 mins):